Brokerages Set Dynavax Technologies Corporation (DVAX) PT at $27.80

Dynavax Technologies Corporation (NASDAQ:DVAX) has earned a consensus recommendation of “Buy” from the eight ratings firms that are currently covering the company, MarketBeat Ratings reports. Three analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12 month price objective among analysts that have covered the stock in the last year is $27.80.

Several brokerages have recently commented on DVAX. Royal Bank Of Canada restated an “outperform” rating and issued a $28.00 price objective (up from $26.00) on shares of Dynavax Technologies Corporation in a report on Monday, September 25th. Cantor Fitzgerald initiated coverage on shares of Dynavax Technologies Corporation in a research note on Friday, September 15th. They set an “overweight” rating and a $24.00 target price on the stock. ValuEngine raised shares of Dynavax Technologies Corporation from a “sell” rating to a “hold” rating in a research note on Thursday, September 7th. Cowen and Company reaffirmed an “outperform” rating and set a $30.00 target price on shares of Dynavax Technologies Corporation in a research note on Thursday, August 10th. Finally, William Blair reaffirmed an “outperform” rating and set a $30.00 target price on shares of Dynavax Technologies Corporation in a research note on Wednesday, August 9th.

TRADEMARK VIOLATION WARNING: “Brokerages Set Dynavax Technologies Corporation (DVAX) PT at $27.80” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another website, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The original version of this piece can be accessed at https://www.dispatchtribunal.com/2017/10/28/brokerages-set-dynavax-technologies-corporation-dvax-pt-at-27-80.html.

A number of large investors have recently modified their holdings of the stock. Bank of America Corp DE boosted its stake in Dynavax Technologies Corporation by 2.3% during the 1st quarter. Bank of America Corp DE now owns 20,356 shares of the biopharmaceutical company’s stock worth $121,000 after purchasing an additional 456 shares during the period. Nationwide Fund Advisors boosted its stake in Dynavax Technologies Corporation by 2.5% during the 2nd quarter. Nationwide Fund Advisors now owns 28,359 shares of the biopharmaceutical company’s stock worth $274,000 after purchasing an additional 692 shares during the period. Parametric Portfolio Associates LLC boosted its stake in Dynavax Technologies Corporation by 3.6% during the 1st quarter. Parametric Portfolio Associates LLC now owns 27,151 shares of the biopharmaceutical company’s stock worth $162,000 after purchasing an additional 939 shares during the period. American International Group Inc. boosted its stake in Dynavax Technologies Corporation by 7.1% during the 1st quarter. American International Group Inc. now owns 23,934 shares of the biopharmaceutical company’s stock worth $142,000 after purchasing an additional 1,584 shares during the period. Finally, Patriot Financial Group Insurance Agency LLC boosted its stake in Dynavax Technologies Corporation by 16.5% during the 2nd quarter. Patriot Financial Group Insurance Agency LLC now owns 12,000 shares of the biopharmaceutical company’s stock worth $108,000 after purchasing an additional 1,700 shares during the period. Hedge funds and other institutional investors own 60.20% of the company’s stock.

Shares of Dynavax Technologies Corporation (DVAX) traded up 2.21% during trading on Friday, hitting $20.85. 1,279,138 shares of the stock were exchanged. The stock’s 50 day moving average price is $21.17 and its 200-day moving average price is $12.25. The company’s market cap is $1.14 billion. Dynavax Technologies Corporation has a one year low of $3.20 and a one year high of $24.45.

Dynavax Technologies Corporation (NASDAQ:DVAX) last issued its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.41) EPS for the quarter, topping the consensus estimate of ($0.50) by $0.09. Dynavax Technologies Corporation had a negative net margin of 1,323.99% and a negative return on equity of 92.09%. The firm had revenue of $0.11 million for the quarter, compared to analyst estimates of $0.15 million. During the same period in the prior year, the business posted ($0.75) EPS. On average, analysts predict that Dynavax Technologies Corporation will post ($1.63) EPS for the current year.

Dynavax Technologies Corporation Company Profile

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Analyst Recommendations for Dynavax Technologies Corporation (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply